Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318937 | 0.91 | CYP2D6 (0.52) | SLC29A1MEN1KMT2ACYP2D6HRH3 | |
| SCHEMBL6313695 | 0.84 | POLB (0.55) | SLC29A1MEN1KMT2ACYP2D6TSHR | |
| SCHEMBL3514854 | 0.82 | ABCB1 (0.45) | MEN1KMT2ACYP2D6HRH3TSHR | |
| SCHEMBL7954379 | 0.79 | SLC29A1 (0.53) | SLC29A1SRCMEN1KMT2ACYP2D6 | |
| SCHEMBL7954984 | 0.76 | SLC29A1 (0.53) | SLC29A1SRCMEN1KMT2ACYP2D6 | |
| Ammonia Solution, Strong SCHEMBL28445735 | 0.75 | MEN1 (0.58) | MEN1KMT2ACYP2D6HRH3TSHR | |
| SCHEMBL3514397 | 0.74 | POLB (0.44) | MEN1KMT2ASMN1; SMN2ABCB1DRD3 | |
| SCHEMBL5885001 | 0.72 | POLB (0.68) | MEN1KMT2ACYP2D6SMN1; SMN2TSHR | |
| SCHEMBL3515182 | 0.71 | CYP2D6 (0.55) | MEN1KMT2ACYP2D6HRH3SMN1; SMN2 | |
| SCHEMBL7953036 | 0.71 | SLC29A1 (0.50) | SLC29A1SRCMEN1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | claimed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | claimed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | claimed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | claimed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | SLC29A1 12/4885SRC 839/4885MEN1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.